| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Choline is an essential nutrient with key roles in brain function, liver metabolism, and cell membrane integrity. Its involvement in Alzheimer’s disease (AD) and cancer is increasingly studied due to its roles in methylation, neurotransmitter synthesis, and cell proliferation. -Choline is a precursor to acetylcholine (ACh), a neurotransmitter critical for memory and cognition. -AD is associated with a loss of cholinergic neurons, leading to decreased ACh levels. -Low choline levels may impair memory and accelerate neurodegeneration. -Dietary choline intake in humans correlates with better cognitive performance and lower risk of dementia in some cohorts. Choline and Cancer -Rapidly dividing cancer cells have high choline demand to support membrane biogenesis. -Almost every tumor cell type investigated showed increased levels of tCho (total Choline) metabolites compared to non-malignant counterparts lecithin and eggs are example soures of choline Choline — an essential quaternary amine nutrient required for phosphatidylcholine and sphingomyelin synthesis, acetylcholine production, lipoprotein export, and one-carbon metabolism. It is best classified as an essential nutrient and dietary supplement ingredient rather than an anticancer drug. Standard abbreviations include Chol and Cho; common supplemental or dietary forms include free choline, choline salts, phosphatidylcholine, lecithin, and glycerophosphocholine derivatives. Major sources are eggs, liver, meat, fish, dairy, legumes, and some cruciferous vegetables. In oncology, the strongest relevance is not as a validated therapeutic but as a metabolic substrate within the Kennedy phospholipid pathway, which is frequently upregulated in proliferating tumors and exploited diagnostically by choline-based imaging. Primary mechanisms (ranked):
Bioavailability / PK relevance: Dietary choline is absorbed from multiple forms, but precise comparative human bioavailability across forms remains incompletely defined. Typical supplements usually provide far less choline than pharmacologic gram-level exposures. Plasma handling is strongly form-dependent, and part of the oral choline load can be diverted by gut microbiota to trimethylamine and then trimethylamine N-oxide. Delivery is therefore systemic but nutritionally scaled, not tumor-selective. In-vitro vs systemic exposure relevance: Many cancer-cell findings concern tumor choline metabolism, choline kinase activity, phosphocholine accumulation, or tracer uptake rather than a direct antitumor effect of ordinary oral choline supplementation. Common in-vitro manipulations of choline availability or pathway enzymes are not directly equivalent to achievable human supplement exposures. Choline itself is concentration-relevant, but its main translational meaning in cancer is usually metabolic support or imaging contrast, not selective tumor killing. Clinical evidence status: Nutritional and neurologic evidence is established for deficiency prevention and cholinergic support, but anticancer therapeutic evidence for choline itself is weak and nonstandard. Human oncology relevance is mainly observational, mechanistic, and diagnostic, especially choline-based PET imaging in prostate cancer recurrence. There is no established role for choline supplementation as a standard anticancer treatment, and in some cancer contexts higher intake has raised concern rather than showing clear benefit. Cancer Mechanistic Table
Alzheimer’s disease and CholineCholine — an essential quaternary amine nutrient required for acetylcholine synthesis, phosphatidylcholine production, membrane turnover, methyl-group metabolism via betaine, and normal neuronal function. In the Alzheimer’s disease context it is best classified as a nutritional and neurochemical support factor rather than a disease-modifying AD drug. Standard abbreviations include Chol and Cho; relevant related forms in the literature include phosphatidylcholine, citicoline (CDP-choline), and alpha-GPC, but these should not be treated as identical to choline itself. Major sources are eggs, liver, meat, fish, dairy, legumes, and supplemental choline salts or phospholipids. The strongest AD relevance is mechanistic and observational: cholinergic dysfunction is central to AD, brain phospholipid turnover is altered, and inadequate choline status may worsen cognitive vulnerability, but direct clinical proof that ordinary choline supplementation meaningfully slows AD progression remains limited. Primary mechanisms (ranked):
Bioavailability / PK relevance: Dietary and supplemental choline is orally bioavailable, but kinetics differ by form and tissue delivery is not brain-selective. Free choline, phosphatidylcholine, and related derivatives have different absorption, metabolism, and CNS relevance. Human translation is constrained by form dependence, microbiome conversion of some oral choline to trimethylamine and trimethylamine N-oxide, and uncertainty about how much routine supplementation materially increases brain cholinergic function in established AD. In-vitro vs systemic exposure relevance: AD relevance is not mainly a high-concentration in-vitro phenomenon. The key issue is long-term nutritional sufficiency and whether chronic intake or specific choline forms improve brain signaling or membrane resilience in vivo. Preclinical animal studies often use prolonged supplementation and show stronger effects than current human intervention data. Clinical evidence status: Preclinical evidence is supportive, and observational human data suggest moderate dietary choline intake may correlate with better cognition or lower dementia risk. However, direct therapeutic evidence for choline itself in diagnosed AD remains limited and inconsistent. Stronger human literature exists for related cholinergic compounds such as citicoline or alpha-GPC, but that should not be conflated with plain choline. Overall status: plausible adjunctive nutritional relevance, not established disease-modifying AD therapy. Alzheimer's Disease Mechanistic Table
|
| Source: HalifaxProj (inhibit) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Type: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer. ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations. However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS. -mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related) "Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways." "During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity." "ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−". "Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules." Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea. Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells." Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers. -It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis. Note: Products that may raise ROS can be found using this database, by: Filtering on the target of ROS, and selecting the Effect Direction of ↑ Targets to raise ROS (to kill cancer cells): • NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS. -Targeting NOX enzymes can increase ROS levels and induce cancer cell death. -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS • Mitochondrial complex I: Inhibiting can increase ROS production • P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes) • Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels • Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels • Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels • SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels • PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels • HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS • Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production. -Inhibiting fatty acid oxidation can increase ROS levels • ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels • Autophagy: process by which cells recycle damaged organelles and proteins. -Inhibiting autophagy can increase ROS levels and induce cancer cell death. • KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes. -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death. • DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels • PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels • SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels • AMPK activation: regulates energy metabolism and can increase ROS levels when activated. • mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels • HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited. • Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels • Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS. -Increasing lipid peroxidation can increase ROS levels • Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation. -Increasing ferroptosis can increase ROS levels • Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability. -Opening the mPTP can increase ROS levels • BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited. • Caspase-independent cell death: a form of cell death that is regulated by ROS. -Increasing caspase-independent cell death can increase ROS levels • DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS • Epigenetic regulation: process by which gene expression is regulated. -Increasing epigenetic regulation can increase ROS levels -PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS) ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx) -HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more -Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research -Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2) Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference -generated from AI and Cancer database ROS rating: +++ strong | ++ moderate | + weak | ± mixed | 0 none NRF2: ↓ suppressed | ↑ activated | ± mixed | 0 none Conditions: [D] dose [Fe] metal [M] metabolic [O₂] oxygen [L] light [F] formulation [T] tumor-type [C] combination
|
| 6107- | Chol, | Choline supplements: An update |
| - | Review, | AD, | NA |
| 3700- | Chol, | Eggs and Health Special Issue |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:340 Target#:275 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid